Dato-DXd 一线治疗晚期三阴性乳腺癌的 III 期随机对照试验
TROPION-Breast02 研究纳入 644 例不适合免疫治疗、既往未治疗的局部复发不可手术或转移性三阴性乳腺癌患者,1:1 随机接受 Dato-DXd 或研究者选择化疗。Dato-DXd 显著改善中位无进展生存期(10.8 个月 vs 5.6 个月)和中位总生存期(23.7 个月 vs 18.7 个月),安全性可控。
要点
- Dato-DXd 组中位 PFS 为 10.8 个月,化疗组为 5.6 个月。
- Dato-DXd 组中位 OS 为 23.7 个月,化疗组为 18.7 个月。
- ≥3 级治疗相关不良事件发生率两组相近,未出现治疗相关死亡。
核心结论
- 在不适合免疫治疗的既往未治疗局部复发不可手术或转移性三阴性乳腺癌患者中,Dato-DXd 较化疗显著改善无进展生存期和总生存期。
- Dato-DXd 的安全性特征与已知一致。
研究设计与样本
- TROPION-Breast02 是一项随机、开放标签、国际、III 期试验。
- 研究纳入不适合免疫治疗的既往未治疗局部复发不可手术或转移性三阴性乳腺癌患者,按 1:1 随机分配接受 Dato-DXd 6 mg/kg 静脉每 3 周一次或研究者选择化疗。
- 随机化按地理区域、无病间期和程序性死亡配体-1 状态分层。
- 双主要终点为无进展生存期(盲法独立中心审查按 RECIST 1.1)和总生存期;意向治疗人群进行疗效分析,至少接受一剂研究治疗的患者进行安全性分析。
- 2022 年 5 月 16 日至 2024 年 6 月 11 日期间,共 644 例患者被随机分配至 Dato-DXd 组(n=323)或化疗组(n=321)。
主要发现
- Dato-DXd 组中位无进展生存期为 10.8 个月(95% CI 8.6-13.0),化疗组为 5.6 个月(95% CI 5.0-7.0),风险比 0.57(99% CI 0.44-0.73),P < 0.0001。
- Dato-DXd 组中位总生存期为 23.7 个月(95% CI 19.8-25.6),化疗组为 18.7 个月(95% CI 16.0-21.8),风险比 0.79(95.01% CI 0.64-0.98),P = 0.029。
- Dato-DXd 组和化疗组分别有 105 例(33%)和 89 例(29%)患者报告 ≥3 级治疗相关不良事件。
- 因治疗相关不良事件导致停药的患者分别为 14 例(4%)和 23 例(7%)。
- 两组均未发生治疗相关死亡。
临床怎么用
- 对于不适合免疫治疗的既往未治疗晚期三阴性乳腺癌患者,Dato-DXd 可作为较化疗改善生存的新选择。
- 用药时需关注治疗相关不良事件,但 ≥3 级不良事件发生率与化疗相近,且因不良事件停药比例较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. PATIENTS AND METHODS: In the randomised, open-label, phase III TROPION-Breast02 trial, patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option were randomly assigned 1:1 to datopotamab deruxtecan (Dato-DXd; 6 mg/kg intravenously every 3 weeks) or investigator's choice of chemotherapy. Randomisation was stratified by geographic location, disease-free interval, and programmed cell death ligand-1 status. Dual primary endpoints were progression-free survival (PFS; blinded independent central review per RECIST version 1.1) and overall survival (OS). Efficacy analyses were performed in the intention-to-treat population. Safety analyses included all patients who received ≥1 dose of study treatment. RESULTS: Between 16 May 2022 and 11 June 2024, 644 patients were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median PFS was 10.8 months [95% confidence interval (CI) 8.6-13.0] with Dato-DXd and 5.6 months (95% CI 5.0-7.0) with chemotherapy [hazard ratio 0.57 (99% CI 0.44-0.73); P < 0.0001]. Median OS was 23.7 months (95% CI 19.8-25.6) and 18.7 months (95% CI 16.0-21.8) with Dato-DXd and chemotherapy, respectively [hazard ratio 0.79 (95.01% CI 0.64-0.98); P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, and TRAEs led to treatment discontinuation in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. CONCLUSIONS: Dato-DXd demonstrated significantly improved PFS and OS versus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. Safety was consistent with the known profile for Dato-DXd.
引用
- Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Ann Oncol. 2026. PMID: 41937088. doi:10.1016/j.annonc.2026.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。